Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 6, 2014 Hepeng Jia	GSK's China troubles continue The company faces official prosecution over accusations of bribery and corruption, litigation from fired employees and an upcoming trial of private investigators employed to look into a blackmail attempt.
Chemistry World July 29, 2013 Hepeng Jia	China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies.
Chemistry World August 29, 2013 Emma Stoye	Couple charged in GSK corruption investigation A UK consultant and his American wife have been charged in relation to the corruption investigation at GlaxoSmithKline in China.
Chemistry World July 12, 2013 Phillip Broadwith	GSK under investigation over corruption in China Chinese police are investigating GlaxoSmithKline over claims of bribery and tax-related crimes.
Chemistry World May 14, 2014 Phillip Broadwith	Chinese police hand GSK bribery case to prosecutors The Chinese state news agency Xinhua has released details of the police investigation, claiming that 46 suspects are involved including Mark Reilly, former manager of GSK China.
Chemistry World April 9, 2014 Emma Stoye	GSK investigates bribery claims in the Middle East GlaxoSmithKline has been accused of bribing doctors and healthcare officials in Iraq in emails leaked to the Wall Street Journal by a whistleblower.
Pharmaceutical Executive August 1, 2013 William Looney	One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future.
Chemistry World July 25, 2014 Hepeng Jia	Scientists and university officials caught up in China's anti-corruption drive Dozens of university officials and leading scientists in China have been arrested or imprisoned as part of the new government's drive to stamp out corruption.
The Motley Fool November 3, 2011 Frank Vinluan	GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders.
Chemistry World April 23, 2014 Phillip Broadwith	GSK corruption investigation widens Pharma giant GlaxoSmithKline has responded to allegations made by the BBC's Panorama program concerning improper conduct by GSK's sales staff in Poland.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
Chemistry World March 11, 2015 Rebecca Trager	Mergers and moves trigger pharma layoffs Downsizing in the pharmaceutical industry is discussed.
BusinessWeek July 8, 2010 Dexter Roberts	The Higher Costs of Bribery in China The U.S. is policing the activities of big multinationals in China more aggressively, with China's own prosecutors sometimes following suit.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
Chemistry World May 16, 2013 Anthony King	GSK partners Save the Children for Africa project Pharma giant GSK is to partner the international charity Save the Children in a five year deal, which it says aims to help save the lives of one million children. The controversial compact offers a blueprint for how businesses and non-government organizations can work together, says GSK.
The Motley Fool July 26, 2011 Cliff D'Arcy	GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors.
Chemistry World January 30, 2007 Bea Perks	BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s.
BusinessWeek January 13, 2011 Nichols & Forsythe	China Wants to Rebalance Its Portfolio Chinese President Hu Jintao's upcoming U.S. visit will include some diplomatic talk and, U.S. officials hope, commercial deals aplenty.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
Entrepreneur May 2005 Mark Henricks	Eastern Influence Chinese companies are becoming increasingly active in buying, merging with and doing joint ventures with smaller U.S companies -- usually in search of technology.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
TIME Asia January 24, 2011 Hannah Beech	China: Two Faces, Fierce and Friendly When it comes to Chinese diplomacy, there always seems to be two sides to the story.
National Defense September 2015 Kopp & Bhatia	U.S. Cracking Down on Defense Industry Corruption Overseas The race for international sales during the past few years has been followed by a wave of government investigations into defense companies for both major and relatively minor violations of the Foreign Corrupt Practices Act.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
The Motley Fool June 14, 2011 Cindy Johnson	Simcere Pharmaceutical Shares Plunged: What You Need to Know Simcere Pharmaceutical Group dropped 10% in intraday trading today as investors continued to doubt the financial health of U.S.-listed Chinese companies.
National Defense November 2015 Bradel & Ralph	Justice Memo Calls for Absolute Cooperation The Foreign Corrupt Practices Act is a statute aimed at eliminating corporate bribery of foreign government officials. A defense contractor doing work overseas must be familiar with its tenets.
The Motley Fool August 8, 2005 Rich Smith	Welcome to America, Daimler-Benz The German half of DaimlerChrysler is under investigation by the Feds. European investors could be in for some rude surprises.
Chemistry World November 16, 2009 Hepeng Jia	Chinese NASDAQ brings little to chemicals industry Similar to the US NASDAQ, most of the listed firms in the Chinese GEM are technology-oriented companies. Classified by industry, electronics and pharmaceutical manufacturers are the biggest groups
Knowledge@Wharton	How Bribery and Other Types of Corruption Threaten the Global Marketplace There's no doubt that corruption, endemic in emerging economies around the world, throws economic development into chaos. Today, the creation of and comment on anti-corruption regimes is a growth industry.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: GlaxoSmithKline on Defense In real life, defense wins championships. This stock analyst includes GlaxoSmithKline on his fantasy football investment team, to shield from a punishing sack by the market.
National Defense August 2006 Shaheen & Bombach	Anti-Bribery Enforcement On the Increase Overseas U.S. government contractors involved in overseas sales recognize the need to comply with the anti-bribery provisions of the U.S. Foreign Corrupt Practices Act.
BusinessWeek January 24, 2005 Bruce Einhorn	So Much For China's "Great Healer" With China's influence growing from Asia to the Americas, President Hu Jintao seems to feel little external pressure for political reform at home. Optimists looking for him to promote a new, more open China should settle in for a long wait.
Fast Company July 2006	China Hands Is China the next economic superpower? Ming Zeng of Cheung Kong business school and Elizabeth Economy from the Council on Foreign Relations hash it out.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
Chemistry World August 21, 2013 Phillip Broadwith	Two way traffic for Chinese drug licensing Chinese companies have trailed behind their Western counterparts in developing innovative new drugs. Very few of those inventions have been considered useful enough to be licensed by western companies. However, that appears to be changing.
Chemistry World July 2, 2012 Andrew Turley	$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Pharmaceutical Executive August 1, 2005 Lena Chow	Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market.
BusinessWeek May 9, 2005 Brian Bremner	Wanted: A Big Broom For China's Banks Beijing is trying to sweep away corruption and bad loans at its huge state lenders before taking them public.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool April 15, 2011 Frank Vinluan	GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands."
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.